What is PleoPharma?
PleoPharma operates at the intersection of biotechnology and neurology, focusing on the development of novel therapeutic interventions for central nervous system disorders and substance abuse. The company distinguishes itself by targeting medical conditions that currently lack FDA-approved treatment options, a market segment characterized by high unmet clinical needs and significant patient suffering. With its lead program having successfully navigated Phase 2 clinical trials, PleoPharma is transitioning from a research-heavy startup into a clinical-stage pharmaceutical developer. The firm maintains a collaborative ecosystem, engaging with healthcare providers and academic researchers to validate its innovative solutions and ensure that its therapeutic candidates meet rigorous safety and efficacy standards.
How much funding has PleoPharma raised?
PleoPharma has raised a total of $68M across 5 funding rounds:
Seed
$1.8M
Series A
$17.5M
Stock/Share Issuance
$6.2M
Series B
$36M
Grant
$6.5M
Seed (2020): $1.8M, investors not publicly disclosed
Series A (2022): $17.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $6.2M, investors not publicly disclosed
Series B (2025): $36M, investors not publicly disclosed
Grant (2026): $6.5M backed by National Institute on Drug Abuse
Key Investors in PleoPharma
National Institute on Drug Abuse
A federal research institution dedicated to advancing scientific knowledge regarding drug use and its consequences, providing critical grant support for high-impact medical research.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PleoPharma?
With the recent capital infusion, PleoPharma is poised to advance its lead therapeutic candidates into late-stage clinical trials. The strategic focus will likely center on scaling manufacturing capabilities and expanding its research infrastructure to support the transition toward potential commercialization. Given the current regulatory environment, the company is expected to prioritize data integrity and clinical trial transparency to facilitate future FDA engagement. Furthermore, the ongoing support from institutional and government partners suggests a robust long-term outlook, as the firm continues to address the systemic challenges associated with substance abuse and neurological health. Investors will be monitoring the firm's ability to maintain its development velocity while managing the inherent risks associated with late-stage pharmaceutical innovation.
See full PleoPharma company page
